A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

By sjmartinez • April 30, 2024

Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15;130(10):1784-1796. doi: 10.1002/cncr.35200. Epub 2024 Jan 23. PMID: 38261444.

Tags: Dermatology, Hematology/Oncology, melanoma, mitogen‐activated protein kinase, nonsmall cell lung cancer, papillary thyroid carcinoma, phosphatidylinositol‐3' kinases, proto‐oncogene proteins B‐RAF, Publications

Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey

Armstrong A, Levit NA, Schneider B, Seiden R, Shi L, Kaplan B, Wu JJ. Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient[...]

A genomic analysis reveals the diversity of cellulosome displaying bacteria

Minor CM, Takayesu A, Ha SM, Salwinski L, Sawaya MR, Pellegrini M, Clubb RT. A genomic analysis reveals the diversity of cellulosome displaying bacteria. Front[...]

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, Sachdeva A, Zomorodian N, Pellegrini M, Li G, Liu S, Drakaki A, Rettig[...]